The Written Procedure was initiated in light of the public offer to the shareholders and warrant holders in ADDvise announced by Amplex AB (“Amplex”) on 10 December 2025 (the “Offer”). The bondholders’ approval of the proposed amendments in the Written Procedure entails that the bondholders’ right to request that their Bonds be repurchased by the Company at a price corresponding to 101 per cent of the nominal amount plus accrued but unpaid interest (the “Put Option”) will not be triggered by (i) a change of control in relation to Amplex or Kenneth Lindqvist or (ii) a delisting of the Company’s shares from Nasdaq First North Premier Growth Market in the event that the Offer is completed.

The agent for the Bonds has received votes in favour of the proposed amendments to the terms and conditions of the Bonds from bondholders representing over 2/3 of the total adjusted nominal amount of the Bonds and the agent for the Bonds has consequently concluded the Written Procedure today. The amended terms and conditions of the Bonds will enter into force today and will be published on the Company’s website. The results of the Written Procedure will also be sent to the bondholders and be available on the agent’s and the Company’s websites.

In accordance with the terms and conditions of the Written Procedure, an early voting fee totalling SEK 1,909,375 will be paid no later than 27 January 2026 to bondholders who fulfilled the conditions for receiving the early voting fee. In addition, a consent fee of SEK 2 million will be paid to the holders of the Bonds through Euroclear Sweden on 10 February 2026. Payment of the consent fee will be made on a pro rata basis to all those who are registered as holders of the Bonds on the record date for the payment on 3 February 2026.

Nordea Bank Abp is acting as consent solicitation agent and Gernandt & Danielsson Advokatbyrå KB is acting as legal advisor in the Written Procedure.

For further information, please contact:

Anna Ljung, board member
Tel: +46 (0) 707 66 60 30, E-mail: anna@ljung.biz

About ADDvise Group

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.7 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company’s Certified Adviser. More information is available at www.addvisegroup.com.